MGO One Seven LLC Purchases 1,464 Shares of Becton, Dickinson and Company (NYSE:BDX)

Key Points

• MGO One Seven LLC increased its stake in Becton, Dickinson and Company by 15.9%, acquiring an additional 1,464 shares, bringing its total holdings to 10,692 shares valued at approximately $2.45 million.
• Institutional investors hold 86.97% of Becton, Dickinson and Company's stock, with several hedge funds recently adjusting their stakes, including new purchases worth up to $34,000.
• Analysts have downgraded Becton, Dickinson and Company to a "hold" rating, with price targets reduced to as low as $185.00 from earlier prices around $261.00.

MGO One Seven LLC grew its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 15.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,692 shares of the medical instruments supplier's stock after buying an additional 1,464 shares during the period. MGO One Seven LLC's holdings in Becton, Dickinson and Company were worth $2,449,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in BDX. Brighton Jones LLC raised its stake in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares during the period. Hara Capital LLC increased its position in shares of Becton, Dickinson and Company by 26.4% during the fourth quarter. Hara Capital LLC now owns 335 shares of the medical instruments supplier's stock valued at $76,000 after buying an additional 70 shares during the period. O Shaughnessy Asset Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 28.3% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 13,002 shares of the medical instruments supplier's stock worth $2,950,000 after buying an additional 2,864 shares in the last quarter. World Investment Advisors boosted its position in shares of Becton, Dickinson and Company by 11.9% in the fourth quarter. World Investment Advisors now owns 15,601 shares of the medical instruments supplier's stock valued at $3,539,000 after acquiring an additional 1,658 shares during the period. Finally, Arete Wealth Advisors LLC grew its stake in Becton, Dickinson and Company by 5.4% during the fourth quarter. Arete Wealth Advisors LLC now owns 3,373 shares of the medical instruments supplier's stock valued at $763,000 after acquiring an additional 174 shares in the last quarter. Institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Price Performance

NYSE BDX traded down $2.06 on Friday, reaching $176.19. 4,688,991 shares of the company's stock traded hands, compared to its average volume of 3,049,202. The stock has a market cap of $50.50 billion, a PE ratio of 33.62, a P/E/G ratio of 1.33 and a beta of 0.20. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The stock has a 50-day simple moving average of $174.93 and a 200 day simple moving average of $200.40. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company had revenue of $5.27 billion for the quarter, compared to analysts' expectations of $5.35 billion. During the same quarter last year, the company earned $3.17 EPS. The firm's revenue was up 4.5% compared to the same quarter last year. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be given a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.4%. Becton, Dickinson and Company's payout ratio is presently 79.39%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Morgan Stanley reduced their price target on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a research report on Tuesday, May 6th. Stifel Nicolaus reduced their target price on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. William Blair cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Wells Fargo & Company lowered Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a report on Thursday, May 1st. Finally, Piper Sandler downgraded shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and lowered their target price for the company from $260.00 to $185.00 in a research note on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $212.88.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Shan sold 1,166 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the sale, the executive vice president directly owned 4,575 shares in the company, valued at $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.